Compared to other cancer types, there are relatively few targeted therapeutic drugs approved for the treatment of esophageal cancer (e.g., human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR-2)), which necessitates more extensive clinical data for support. This evidence concerns the gene KDR and esophageal cancer.